LENZ Therapeutics, Inc.

Lens Therapeutics, Inc. (NASDAQ: LENZ) is a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. The company's website is www.lenstherapeutics.com.

The company's primary product is VIZZ (aceclidine ophthalmic solution) 1.44%, a once-daily eye drop approved by the FDA in July 2025 for the treatment of presbyopia, a condition affecting approximately 1.8 billion people globally and 128 million people in the United States. VIZZ represents the first and only FDA-approved aceclidine-based eye drop for presbyopia and is powered by aceclidine, a pupil-selective miotic that achieves a sub-2mm pupil diameter to extend depth of focus and improve near vision without causing myopic shift or negatively impacting distance vision. The product offers rapid onset of action, with 71 percent of users achieving three-lines or greater improvement in near visual acuity within 30 minutes, and maintains efficacy for up to 10 hours.

Lens Therapeutics commercially launched VIZZ in the United States in August 2025, with professional product sample distribution initiated in October 2025 and retail pharmacy availability beginning in November 2025. The company employs a direct-to-eye care professional sales and marketing strategy targeting approximately 15,000 eye care professionals who prescribed over 85 percent of pharmaceutical presbyopia prescriptions in 2022. The company also operates a direct-to-consumer marketing campaign to build brand loyalty among presbyopes.

The company estimates the addressable U.S. market opportunity for presbyopia treatment at over three billion dollars, based on an assumed six percent adoption rate among the presbyope population and a one-month supply price of seventy-nine dollars with an estimated forty-two percent refill rate. VIZZ has patent protection extending until 2044 in the United States and benefits from five years of new chemical entity exclusivity expiring in July 2030.

Beyond the United States, Lens Therapeutics has established licensing and distribution partnerships internationally, including agreements with CORXEL Pharmaceuticals for Greater China, Lotus Pharmaceutical for South Korea and Southeast Asia, Laboratoires Théa for Canada, and Lunatus Global Medical Supplies for the Middle East region.